Transmembrane protein ADAM29 facilitates cell proliferation, invasion and migration in clear cell renal cell carcinoma

References

• Kuthi L, Jenei A, Hajdu A, Németh I, Varga Z, Bajory Z, Pajor L, Iványi B. Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res. 2017;23(3):689–98.
   PubMed Web of Science ®Google Scholar
• Sobczuk P, Brodziak A, Khan MI, Chhabra S, Fiedorowicz M, Wełniak-Kamińska M, Synoradzki K, Bartnik E, Cudnoch-Jędrzejewska A, Czarnecka AM, et al. Choosing the right animal model for renal cancer research. Transl Oncol. 2020;13(3):100745.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
   PubMed Web of Science ®Google Scholar
• Roemeling CAV, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, et al. Abstract LB-111: neuronal pentraxin 2: a novel tumor-specific molecular target that mediates clear cell renal cell carcinoma malignancy. 2014. 74:LB-111.
   Google Scholar
• Xu L, Chang Y, An H, Zhu Y, Yang Y, Xu J. High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. Urol Oncol. 2015;33:340.e1–8.
   Web of Science ®Google Scholar
• Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A. The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nat Rev Nephrol. 2019;15(7):423–33.
   PubMed Web of Science ®Google Scholar
• Feng H, Zhang Y, Liu K, Zhu Y, Yang Z, Zhang X, Liu Y. Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue. Int J Cancer. 2017;140(11):2526–34.
   PubMed Web of Science ®Google Scholar
• Sawicki P, Kaźmierczak W, Burduk P, Kaźmierczak H. Multiple metastases of renal clear cell carcinoma to the organs of the head. Contemp Oncol (Pozn)). 2014;18(6):448–51.
   PubMedGoogle Scholar
• Souza JSM, Lisboa ABP, Santos TM, Andrade MVS, Neves VBS, Teles-Souza J, Jesus HNR, Bezerra TG, Falcão VGO, Oliveira RC, et al. The evolution of ADAM gene family in eukaryotes. Genomics. 2020;112(5):3108–16.
   PubMed Web of Science ®Google Scholar
• He H, Puerta DT, Cohen SM, Rodgers KR. Structural and spectroscopic study of reactions between chelating zinc-binding groups and mimics of the matrix metalloproteinase and disintegrin metalloprotease catalytic sites: the coordination chemistry of metalloprotease inhibition. Inorg Chem. 2005;44(21):7431–42.
   PubMed Web of Science ®Google Scholar
• Schwettmann L, Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr Purif. 2001;21(1):65–70.
   PubMed Web of Science ®Google Scholar
• White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003;15(5):598–606.
   PubMed Web of Science ®Google Scholar
• Mullooly M, McGowan PM, Crown J, Duffy MJ. The ADAMs family of proteases as targets for the treatment of cancer. Cancer Biol Ther. 2016;17(8):870–80.
   PubMed Web of Science ®Google Scholar
• Conrad C, Benzel J, Dorzweiler K, Cook L, Schlomann U, Zarbock A, Slater EP, Nimsky C, Bartsch JW. ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clin Sci (Lond)). 2019;133(1):83–99.
   PubMed Web of Science ®Google Scholar
• Li H, Guo X, Li Q, Ran P, Xiang X, Yuan Y, Dong T, Zhu B, Wang L, Li F, et al. Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells. Cancer Manag Res. 2018;10:6599–609.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang S. Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro. Oncol Lett. 2018;16:1483–90.
   PubMed Web of Science ®Google Scholar
• Roemer A, Schwettmann L, Jung M, Roigas J, Kristiansen G, Schnorr D, Loening S, Jung K, Lichtinghagen R. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. 2004;11:529–36.
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Tsai JP, Yang SF, Chiou HL, Lin CL, Hsieh YH, et al. Fisetin suppresses the proliferation and metastasis of renal cell carcinoma through upregulation of MEK/ERK-targeting CTSS and ADAM9. Cells. 2019;8:948.
   Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–24.
   PubMed Web of Science ®Google Scholar
• Meissner MA, McCormick BZ, Karam JA, Wood CG. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018;18(7):663–71.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Lepore Signorile M, Grossi V, Sanese P, Napoli A, Maiorano E, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957–85.
   PubMedGoogle Scholar
• Lucarelli G, Ditonno P, Bettocchi C, Vavallo A, Rutigliano M, Galleggiante V, Larocca AMV, Castellano G, Gesualdo L, Grandaliano G, et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol Oncol. 2017;35:461.e415–27.
   Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S, et al. Increased expression of the autocrine motility factor is associated with poor prognosis in patients with clear cell-renal cell carcinoma. Medicine (Baltimore). 2015;94:e2117.
   PubMed Web of Science ®Google Scholar
• Gigante M, Lucarelli G, Divella C, Netti GS, Pontrelli P, Cafiero C, et al. Soluble serum αKlotho is a potential predictive marker of disease progression in clear cell renal cell carcinoma. Medicine (Baltimore). 2015;94:e1917.
   PubMed Web of Science ®Google Scholar
• Papale M, Vocino G, Lucarelli G, Rutigliano M, Gigante M, Rocchetti MT, Pesce F, Sanguedolce F, Bufo P, Battaglia M, et al. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget. 2017;8(25):40412–24.
   PubMedGoogle Scholar
• Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, De Marco S, Bovo G, Cifola I, Mangano E, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–15.
   PubMedGoogle Scholar
• Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, Castellano G, Bettocchi C, Ditonno P, Battaglia M, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407.
   PubMed Web of Science ®Google Scholar
• Zhao M, Jia W, Jiang WG, Wang P, Du G, Cheng S, Song M. ADAM29 expression in human breast cancer and its effects on breast cancer cells in vitro. Anticancer Res. 2016;36(3):1251–8.
   PubMed Web of Science ®Google Scholar
• Shan Q, Lou X, Xiao T, Zhang J, Sun H, Gao Y, Cheng S, Wu L, Xu N, Liu S, et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett. 2013;328(1):160–7.
   PubMed Web of Science ®Google Scholar
• John RR, Malathi N, Ravindran C, Anandan S. Mini review: multifaceted role played by cyclin D1 in tumor behavior. Indian J Dent Res. 2017;28(2):187–92.
   PubMedGoogle Scholar
• Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl)). 2016;94(12):1313–26.
   PubMed Web of Science ®Google Scholar
• Wang Q-S, Li F, Liao Z-Q, Li K, Yang X-L, Lin Y-Y, Zhao Y-L, Weng S-Y, Xia Y, Ye Y, et al. Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients. Cancer Med. 2019;8(9):4100–9.
   PubMed Web of Science ®Google Scholar
• Cardano M, Tribioli C, Prosperi E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targets. 2020;20(4):240–252.
   PubMed Web of Science ®Google Scholar
• Heine S, Kleih M, Giménez N, Böpple K, Ott G, Colomer D, Aulitzky WE, van der Kuip H, Silkenstedt E. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. J Hematol Oncol. 2018;11(1):112.
   PubMedGoogle Scholar
• Park GH, Sung JH, Song HM, Jeong JB. Anti-cancer activity of Psoralea fructus through the downregulation of cyclin D1 and CDK4 in human colorectal cancer cells. BMC Complement Altern Med. 2016;16(1):373.
   PubMedGoogle Scholar
• Bartova E, Suchankova J, Legartova S, Malyskova B, Hornacek M, Skalnikova M, et al. PCNA is recruited to irradiated chromatin in late S-phase and is most pronounced in G2 phase of the cell cycle. Protoplasma. 2017;254:2035–43.
   PubMed Web of Science ®Google Scholar
• Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci. 2007;12:1475–87.
   PubMedGoogle Scholar
• Wieczorek E, Jablonska E, Wasowicz W, Reszka E. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015;36(1):163–75.
   PubMedGoogle Scholar
• Lee L-Y, Wu C-M, Wang C-C, Yu J-S, Liang Y, Huang K-H, Lo C-H, Hwang T-L. Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol Histopathol. 2008;23(5):515–21.
   PubMed Web of Science ®Google Scholar
• Niu H, Li F, Wang Q, Ye Z, Chen Q, Lin Y. High expression level of MMP9 is associated with poor prognosis in patients with clear cell renal carcinoma. PeerJ. 2018;6:e5050.
   PubMed Web of Science ®Google Scholar
• Andreiana BC, Stepan AE, Mărgăritescu C, Tăisescu O, Osman A, Simionescu C. Snail and E-cadherin immunoexpression in clear cell renal cell carcinoma. Curr Health Sci J. 2019;45(2):185–9.
   PubMedGoogle Scholar